Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Trading Outlook
REGENERON PHAR closed up 16.300 at 520.220. Volume was 81% below average (consolidating) and Bollinger Bands were 79% wider than normal.
Open High Low Close Volume___
521.210 524.980 517.020 520.220 159,192
Technical Outlook
Short Term: Neutral
Intermediate Term: Bearish
Long Term: Bullish
Moving Averages: 10-period 50-period 200-period
Close: 480.31 528.45 482.06
Volatility: 44 59 41
Volume: 1,031,855 922,591 830,384
Short-term traders should pay closer attention to buy/sell arrows while intermediate/long-term traders should place greater emphasis on the Bullish or Bearish trend reflected in the lower ribbon.
Summary
REGENERON PHAR gapped up today (bullish) on light volume. Possibility of a Common Gap which usually coincides with a lack of interest in the security. Common Gaps are fairly irrelevent for forecasting purposes. Four types of price gaps exist – Common, Breakaway, Runaway, and Exhaustion. Gaps acts as support/resistance.
REGENERON PHAR is currently 7.9% above its 200-period moving average and is in an downward trend. Volatility is high as compared to the average volatility over the last 10 periods. Our volume indicators reflect volume flowing into and out of REGN.O at a relatively equal pace (neutral). Our trend forecasting oscillators are currently bearish on REGN.O and have had this outlook for the last 35 periods. Our momentum oscillator has set a new 14-period high while the security price has not. This is a bullish divergence.
HEFFX Candlesticks
A black body occurred (because prices closed lower than they opened).
During the past 10 bars, there have been 7 white candles and 3 black candles for a net of 4 white candles. During the past 50 bars, there have been 24 white candles and 26 black candles for a net of 2 black candles.
A rising window occurred (where the top of the previous shadow is below the bottom of the current shadow). This usually implies a continuation of a bullish trend. There have been 3 rising windows in the last 50 candles–this makes the current rising window even more bullish.
A spinning top occurred (a spinning top is a candle with a small real body). Spinning tops identify a session in which there is little price action (as defined by the difference between the open and the close). During a rally or near new highs, a spinning top can be a sign that prices are losing momentum and the bulls may be in trouble.
Momentum Indicators
Momentum is a general term used to describe the speed at which prices move over a given time period. Generally, changes in momentum tend to lead to changes in prices. This expert shows the current values of four popular momentum indicators.
Stochastic Oscillator
One method of interpreting the Stochastic Oscillator is looking for overbought areas (above 80) and oversold areas (below 20). The Stochastic Oscillator is 93.8083. This is an overbought reading. However, a signal is not generated until the Oscillator crosses below 80 The last signal was a buy 8 period(s) ago.
Relative Strength Index (RSI)
The RSI shows overbought (above 70) and oversold (below 30) areas. The current value of the RSI is 54.93. This is not a topping or bottoming area. A buy or sell signal is generated when the RSI moves out of an overbought/oversold area. The last signal was a buy 8 period(s) ago.
Commodity Channel Index (CCI)
The CCI shows overbought (above 100) and oversold (below -100) areas. The current value of the CCI is 110.This is an overbought reading. However, a signal isn’t generated until the indicator crosses below 100. The last signal was a buy 7 period(s) ago.
MACD
The Moving Average Convergence/Divergence indicator (MACD) gives signals when it crosses its 9 period signal line. The last signal was a buy 2 period(s) ago.
Regeneron Pharmaceuticals, Inc., incorporated on January 11, 1988, is an integrated biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, colorectal cancer, and a rare inflammatory condition and has product candidates under development in other areas, including hypercholesterolemia, oncology, rheumatoid arthritis (RA), asthma and atopic dermatitis. The Company’s marketed products include EYLEA (aflibercept) injection, ZALTRAP (ziv-aflibercept) injection for intravenous infusion and ARCALYST (rilonacept) injection for subcutaneous use. The Company has 17 product candidates in clinical development. Its product candidates consist of two trap-based clinical programs and 15 human monoclonal antibody product candidates. The Company has generated each of the antibodies using its VelocImmune technology.
EYLEA is in Phase III clinical development for the treatment of wet AMD (Asia) and DME (Asia) in collaboration with Bayer HealthCare. EYLEA is also being studied in combination with an antibody to Platelet Derived Growth Factor Receptor Beta (PDGFR-beta) and an antibody to angiopoietin-2 (Ang2). The Company in collaboration with Sanofi develops ZALTRAP, which is in Phase III clinical development for the treatment of metastatic colorectal cancer in the Asia-Pacific region. PRALUENT (alirocumab/REGN727) is an antibody that is given to PCSK9. It is in Phase III clinical development for low-density lipoprotein (LDL) cholesterol reduction and for the prevention of cardiovascular events. Sarilumab (REGN88) is an antibody to the interleukin-6 receptor (IL-6R). It is in clinical development in rheumatoid arthritis (Phase III) and non-infectious uveitis (Phase II).
Dupilumab (REGN668) is an antibody to the interleukin-4 receptor (IL-4R) alpha subunit. It is in clinical development in atopic dermatitis (Phase III), asthma (Phase IIb), chronic sinusitis with nasal polyps (CSwNP) (Phase II) and eosinophilic esophagitis (EoE) (Phase II). REGN1033 is an antibody to myostatin (GDF8), which is in Phase II clinical development in skeletal muscle disorders. REGN2222 is an antibody against respiratory syncytial virus (RSV). It is in Phase I clinical study. REGN2176-3 is a combination product consisting of an antibody to PDGFR-beta co-formulated with EYLEA for use in ophthalmology, via intravitreal administration. It is in Phase I clinical study for the treatment of wet AMD. REGN1908-1909 is an antibody combination, which is in Phase I/Phase II clinical development against allergic disease. REGN1400 is an antibody to ErbB3, which is in Phase I clinical development in oncology.
The Company’ REGN1154 is an antibody against an undisclosed target, which has completed its Phase I clinical study in Australia. REGN1500 is an antibody to Angptl-3, which is in Phase I clinical development. REGN1193 is an antibody, which is in Phase I clinical development against an undisclosed target. REGN1979 is a Bispecific antibody against both CD20 and CD3 for use in oncology, and is in Phase I of clinical study. REGN910-3 is a combination product consisting of an antibody to Ang2 co-formulated with EYLEA for use in ophthalmology, via intravitreal administration. Its Phase I clinical study was initiated in the fourth quarter of 2014. REGN2810 is an antibody to PD-1.. Fasinumab (REGN475) is an antibody to Nerve Growth Factor (NGF). It is in development for the treatment of pain on partial clinical hold by the United States Food and Drug Administration (FDA) limiting duration of trials in osteoarthritis to 16 weeks.
EYLEA
The Company’s EYLEA (aflibercept) Injection, which is known as VEGF Trap-Eye in the scientific literature, is available in the United States, European Union (EU), Japan and certain other countries outside the United States for the treatment of neovascular age-related macular degeneration (wet AMD) and macular edema following central retinal vein occlusion (CRVO). The Company has approval for EYLEA from the United States Food and Drug Administration (FDA), European Commission, and Japanese Ministry of Health, Labour and Welfare (MHLW), respectively, for the treatment of diabetic macular edema (DME). The Company also has approval for EYLEA from the Japanese MHLW for myopic choroidal neovascularization (mCNV). The Company has approval for EYLEA from the FDA for the treatment of macular edema following retinal vein occlusion (RVO), which includes macular edema following branch retinal vein occlusion (BRVO). The Company has approval for EYLEA from the European Committee for Medicinal Products for Human Use (CHMP) for the treatment of visual impairment due to macular edema secondary to CRVO or BRVO. EYLEA is in Phase III clinical development for the treatment of wet AMD (Asia) and DME (Asia) in collaboration with Bayer HealthCare. EYLEA is also being studied in combination with an antibody to platelet derived growth factor receptor beta (PDGFR-beta) and an antibody to angiopoietin-2 (Ang2).
ZALTRAP
The Company’s ZALTRAP (ziv-aflibercept) Injection for Intravenous Infusion, which is known as VEGF Trap in the scientific literature, is available in the United States, European Union (EU), and certain other countries for treatment of patients with metastatic colorectal cancer (mCRC) that is resistant to or has progressed following an oxaliplatin-containing regimen, in combination with 5-fluorouracil, leucovorin, irinotecan (FOLFIRI). The Company has submitted regulatory applications for marketing authorization of ZALTRAP for the treatment of previously treated mCRC patients in other countries. The Company in collaboration with Sanofi develops and commercializes ZALTRAP. ZALTRAP is in Phase III clinical development for the treatment of metastatic colorectal cancer in the Asia-Pacific region.
ARCALYST
The Company’s ARCALYST (rilonacept) Injection for subcutaneous use is available in the United States. The Company develops ARCALYST (rilonacept) Injection for the treatment of cryopyrin-associated periodic syndromes (CAPS) in adults and children of 12 years and above.
The Company competes with Genentech, Roche, Novartis AG, Pfizer Inc., Bayer HealthCare, Allergan, Inc., Eli Lilly and Company, AbbVie Inc., Sanofi, Merck & Co., Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Johnson & Johnson, GlaxoSmithKline plc, Aveo Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Alder Biopharmaceuticals, Inc. Ablynx, R-Pharm, Chengdu Kanghong Pharmaceutical Group, Ophthotech Corporation and Pfenex Inc.
The post Regeneron Pharmaceuticals Inc (NASDAQ:REGN) Trading Outlook appeared first on Live Trading News.